RE:RE:RE:RE:RE:So many questions ....Exactly, MM. Thanks for posting. I wholeheartedly agree with what you are saying even though I am sure I will get bashed for it.
mercedesman wrote: “If I didn't know better, you are trying too hard to prop the stock price up..
Your comments regarding the fact that no insiders have sold is an indicator of good things to come, is asinine.
If any of them sold a million (less than 1%) shares the SP would dive to depths we haven't (or want) to see.”
-Davidking
They’re too smart for that DV. If you wanted out, you’d promote first, thereby creating demand – as has been pointed out many times in the past by others on SH. That’s how the stock market works. It’s 101.
Creating demand however brings with it: additional shareholders to babysit, higher risk of lawsuits, higher priced option grants, and perhaps a more uncomfortable ultimate buyer
(who quite naturally would prefer to buy below FMV and retain some upside for themselves). If I had to guess (and I do) it’s likely one or more of those things in combination, that the powers that be would prefer not to have to deal with as a by-product of promotion.
No my dear DV, it’s not the lack of insider selling that is most telling. Ironically, it’s the lack of promotion in tandem, that is most telling.
It would seem that it’s all about the end-game. Not the stock price pre-FDA, but the buyout price post FDA. I think even Howsaboutit could agree with that.
I’ve always advocated for a true reflection of FMV all along -based on a more complete discussion of the size of the market for all products in their repertoire (including EAA and SAM pump), in addition to the probabilities and risks associated with each binary outcome. We gets lots of colour on the risks and downside negativity, and very little on possible rewards. So you see, I am only here to try to balance things out. That’s my role. And it’s likely why my posts have been tolerated while others are censored. I simply demonstrate that it is possible for someone to figure out both the up and the downside, and to get a better estimate/idea of the probabilities of either happening. But I am a lonely voice in the wilderness, and not enough others Care to scratch the surface of the story (Georgie might be one that’s close), nor can they do probability math – so the SP languishes. If it was trading on a US market there would be more demand by default, but I guess we can’t have that for reasons previously alluded to (including greater on-going scrutiny by the SEC).
The fact that I think too much emphasis has been placed on the negative, and not enough on the positive, DOES NOT MEAN I am trying to prop up the stock price (artificially).
I’m simply stating my opinion that the current price doesn’t reflect, for a variety of reasons, the full & true picture, which includes the POTENTIAL for a large upside move, in a very short period of time. Not to mention a potentially higher floor price (than some might expect) should the FDA turn down PMX in the short term, the one new Sepsis tool to come along in 15 years that could help to reduce the death toll by 10’s of thousands annually in the US alone.
Thanx for playing your part…and for having this enlightened discussion with me.
MM